胰高血糖素样肽-1受体激动剂司美格鲁肽和聚乙二醇洛塞那肽治疗肥胖症的研究进展

Advances in the Treatment of Obesity with the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Polyethylene Glycol Losenatide

全球肥胖患病率持续上升,对个人和公共卫生系统构成重大健康挑战。胰高血糖素样肽-1(GLP-1)激动剂司美格鲁肽和聚乙二醇洛塞那肽已被证明可以降低食欲、减少能量摄入并延迟胃排空,从而导致体重减轻。本文就GLP-1受体激动剂司美格鲁肽和聚乙二醇洛塞那肽治疗肥胖症的作用机制、临床研究及安全性等内容进行综述。

The global prevalence of obesity continues to rise,posing a major health challenge for individuals and public health systems.The glucagon-like peptide-1(GLP-1)agonists Semaglutide and peglosenatide have been shown to reduce appetite,reduce energy intake and delay gastric emptying,leading to weight loss.This article reviews the mechanism of action,clinical studies and safety of GLP-1 receptor agonists Semaglutide and peglosenatide in the treatment of obesity.